Answers are grounded in this paper and cite their sources.
Clinical trials evaluate axatilimab’s efficacy and safety in chronic graft-versus-host disease, indicating potential benefits but unanswered questions remain.
Axatilimab has demonstrated safety, tolerability and efficacy in clinical trials; however, many questions remain unanswered including long-term safety data, efficacy when compared to other cGVHD therapies, risks and benefits of axatilimab in combination, and role in earlier lines of cGVHD treatment.
No takes yet. Share an insight, caveat, or question.
Chhabra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: